contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


modular-finance-ir-consensus-xvivo-perfusion-consensus-estimates-q3-2024

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Xvivo Perfusion är verksamt inom medicinteknik. Bolaget tillhandahåller lösningar för transplantation av lungor. Exempel på produkter som bolaget levererar innefattar kanyler, organförvaring samt kyllösningar. Produkterna vidaresäljs till kliniker och forskningsinstitut runtom den globala marknaden, med störst närvaro inom Norden och Europa. Bolaget kom till via en avknoppning från Vitrolife under 2012 och har sitt huvudkontor i Göteborg.

Xvivo Perfusion

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.Number of contributors: 5 (all of which have been updated or confirmed before the report)KPI (MSEK, unless otherwise specified...

<div class="mfn-body"><p>Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.</p><p>Number of contributors: 5 (all of which have been updated or confirmed before the report)</p><table><tbody><tr><td rowspan="1" colspan="1"><strong>KPI (MSEK, unless otherwise specified)</strong></td><td rowspan="1" colspan="1" align="right"><strong>Q3 2024E</strong></td></tr><tr><td rowspan="1" colspan="1">Net sales</td><td rowspan="1" colspan="1" align="right">208</td></tr><tr><td rowspan="1" colspan="1">Organic growth in local currency (%)</td><td rowspan="1" colspan="1" align="right">37.2</td></tr><tr><td rowspan="1" colspan="1">Gross profit</td><td rowspan="1" colspan="1" align="right">155</td></tr><tr><td rowspan="1" colspan="1">EBITDA</td><td rowspan="1" colspan="1" align="right">41</td></tr><tr><td rowspan="1" colspan="1">EBIT</td><td rowspan="1" colspan="1" align="right">23</td></tr><tr><td rowspan="1" colspan="1">Net profit</td><td rowspan="1" colspan="1" align="right">21</td></tr><tr><td rowspan="1" colspan="1">Earnings per share (SEK)</td><td rowspan="1" colspan="1" align="right">0.69</td></tr><tr><td rowspan="1" colspan="1"><strong>Net sales per segment:</strong></td><td rowspan="1" colspan="1" align="right"><br></td></tr><tr><td rowspan="1" colspan="1">Thoracic</td><td rowspan="1" colspan="1" align="right">136</td></tr><tr><td rowspan="1" colspan="1">Abdominal</td><td rowspan="1" colspan="1" align="right">47</td></tr><tr><td rowspan="1" colspan="1">Services</td><td rowspan="1" colspan="1" align="right">24</td></tr></tbody></table><p>XVIVO Perfusion’s Q3 report will be released on Thursday, 24 October, at 07:30 CEST.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/bb4319e2-33de-43b5-b451-67cd29b90515/xvivo-perfusion-consensus-estimates-q3-2024.pdf" class="mfn-generated mfn-primary">XVIVO Perfusion – Consensus estimates Q3 2024</a></p></div>

Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q3 2024

Wall Streetin arvostustasoihin verrattuna Eurooppakin näyttää nyt houkuttelevalta

Federal Reserven korkopäätös: Kiire loppui tähän

Drug development investment: Value creation through M&As and licensing agreements

EKP:n korkopäätös: Keskuspankki ilman rajoitteita

Euroalueen ostopäälliköt: Onks sen jälkeen vielä mäki?

KPI (MSEK, unless otherwise specified)	Q3 2024E
Net sales	208
Organic growth in local currency (%)	37.2
Gross profit	155
EBITDA	41
EBIT	23
Net profit	21
Earnings per share (SEK)	0.69
Net sales per segment:
Thoracic	136
Abdominal	47
Services	24

Beställ vårt nyhetsbrev — inget användarkonto krävs!